首页>
外国专利>
PREDICTING RESPONSE TO ANTI-CD20 THERAPY IN DLBCL PATIENTS
PREDICTING RESPONSE TO ANTI-CD20 THERAPY IN DLBCL PATIENTS
展开▼
机译:预测DLBCL患者对抗CD20治疗的反应
展开▼
页面导航
摘要
著录项
相似文献
摘要
This invention provides methods, compositions, and kits relating to biomarkers whose expression levels are correlated with diffuse large B-cell lymphoma (DLCBL) patients' response to treatment with a CD20 antagonist, such as a CD20 antibody, exemplified by rituximab. The methods, compositions, and kits of the invention can be used to identify DLBCL patients who are likely or not likely, to respond to anti-CD20 treatments.
展开▼